[go: up one dir, main page]

HUP0002701A1 - Esszenciális zsírsavakat és bioaktív diszulfidokat tartalmazó gyógyhatású és dietikus készítmények - Google Patents

Esszenciális zsírsavakat és bioaktív diszulfidokat tartalmazó gyógyhatású és dietikus készítmények

Info

Publication number
HUP0002701A1
HUP0002701A1 HU0002701A HUP0002701A HUP0002701A1 HU P0002701 A1 HUP0002701 A1 HU P0002701A1 HU 0002701 A HU0002701 A HU 0002701A HU P0002701 A HUP0002701 A HU P0002701A HU P0002701 A1 HUP0002701 A1 HU P0002701A1
Authority
HU
Hungary
Prior art keywords
essential fatty
disulphides
bioactive
therapeutic
fatty acids
Prior art date
Application number
HU0002701A
Other languages
English (en)
Inventor
David Frederick Horrobin
Hans-Jürgen Tritschler
Original Assignee
Asta Medica A.G.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10816266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0002701(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asta Medica A.G. filed Critical Asta Medica A.G.
Publication of HUP0002701A1 publication Critical patent/HUP0002701A1/hu
Publication of HUP0002701A3 publication Critical patent/HUP0002701A3/hu
Publication of HU226673B1 publication Critical patent/HU226673B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Atalálmány tárgya egy esszenciális zsírsav, előnyösen az n-6vagy az n-3metabolikus ágban, előnyösen a 6. deszaturációs lépés után képződőesszenciális zsírsav és egy biokompatibilis diszulfid, előnyösentiooktánsav vagy egy rokon származékának alkalmazása cukorbetegség,inzulinrezisztencia vagy a cukorbetegség szövődményeinek a kezelésérevagy megelőzésére alkalmas gyógyszerkészítmény előállítására. Ó
HU0002701A 1997-07-22 1998-07-22 Use of essential fatty acids and bioactive disulphides for the preparation of therapeutic and dietary compositions HU226673B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9715444A GB9715444D0 (en) 1997-07-22 1997-07-22 Therapeutic and dietary compositions
PCT/GB1998/002155 WO1999004782A1 (en) 1997-07-22 1998-07-22 Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides

Publications (3)

Publication Number Publication Date
HUP0002701A1 true HUP0002701A1 (hu) 2001-01-29
HUP0002701A3 HUP0002701A3 (en) 2001-03-28
HU226673B1 HU226673B1 (en) 2009-06-29

Family

ID=10816266

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002701A HU226673B1 (en) 1997-07-22 1998-07-22 Use of essential fatty acids and bioactive disulphides for the preparation of therapeutic and dietary compositions

Country Status (30)

Country Link
US (1) US6630157B1 (hu)
EP (2) EP1419769A1 (hu)
JP (1) JP4476479B2 (hu)
KR (1) KR100545630B1 (hu)
CN (2) CN1679532A (hu)
AT (1) ATE262900T1 (hu)
AU (1) AU739876B2 (hu)
BG (1) BG64349B1 (hu)
BR (1) BR9812102A (hu)
CA (1) CA2297082C (hu)
CZ (1) CZ298527B6 (hu)
DE (1) DE69822832T2 (hu)
DK (1) DK0994705T3 (hu)
ES (1) ES2214717T3 (hu)
GB (2) GB9715444D0 (hu)
HU (1) HU226673B1 (hu)
IL (2) IL134090A0 (hu)
MY (1) MY127930A (hu)
NO (1) NO327173B1 (hu)
NZ (1) NZ502278A (hu)
PL (1) PL194059B1 (hu)
PT (1) PT994705E (hu)
RO (1) RO121318B1 (hu)
RU (1) RU2205004C2 (hu)
SK (1) SK285836B6 (hu)
TR (1) TR200000178T2 (hu)
TW (1) TW565444B (hu)
UA (1) UA66363C2 (hu)
WO (1) WO1999004782A1 (hu)
ZA (1) ZA986480B (hu)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
DE10027968A1 (de) * 2000-06-08 2001-12-13 Asta Medica Ag Mittel zur Therapie von Demenzen
US20020132781A1 (en) * 2000-10-06 2002-09-19 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and A 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor
US8669282B2 (en) * 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
DE10125882B4 (de) * 2001-05-28 2007-03-29 Esparma Gmbh Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus
NL1019368C2 (nl) * 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US6974592B2 (en) * 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
ATE439127T1 (de) * 2002-06-17 2009-08-15 Medestea Res & Production S P Langkettige ungesättigte sauerstoffhaltige verbindungen und deren verwendung im therapeutischen, kosmetischen und diätetischen bereich
EP2384750A1 (en) * 2002-09-27 2011-11-09 Martek Biosciences Corporation Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
BR0314710A (pt) * 2002-09-27 2005-07-26 Martek Biosciences Corp Terapia profilática com ácido decosahexenóico para pacientes com inflamação subclìnica
MX272648B (es) * 2002-11-04 2009-12-10 Ocean Nutrition Canada Ltd Microcapsulas que tienen multiples cortezas y metodo para la preparacion de las mismas.
US20060233863A1 (en) 2003-02-10 2006-10-19 Enzymotec Ltd. Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy
US7705016B2 (en) 2003-02-13 2010-04-27 Albert Einstein College Of Medicine Of Yeshiva University Regulation of food intake by modulation of long-chain fatty acyl-CoA levels in the hypothalamus
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
US8633246B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Omega-3 fatty acids for osteoarthritis
US8633247B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
CA2529749C (en) * 2003-08-11 2012-03-20 Hill's Pet Nutrition, Inc. Omega-3 fatty acids for the treatment of canine osteoarthritis
WO2005018632A1 (en) 2003-08-18 2005-03-03 Btg International Limited Treatment of neurodegenerative conditions
US20050261367A1 (en) * 2004-03-29 2005-11-24 Howard Murad Methods for treating dermatological and other health-related conditions in a patient
JP5667737B2 (ja) * 2004-07-01 2015-02-12 ネステク ソシエテ アノニム イヌ変形性関節症食餌製剤
CN103223160B (zh) 2004-07-19 2015-02-18 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
WO2006016357A1 (en) * 2004-08-09 2006-02-16 Enzymotec Ltd. Food products for diabetics
AU2005270831B2 (en) 2004-08-10 2011-08-25 Enzymotec Ltd. Mixture of phytosterol ester(s) and 1, 3-diglyceride(s) for use in the treatment of medical conditions
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0428166D0 (en) * 2004-12-23 2005-01-26 Efamol Ltd Use of essentially fatty acid molecules
US8034450B2 (en) * 2005-01-21 2011-10-11 Ocean Nutrition Canada Limited Microcapsules and emulsions containing low bloom gelatin and methods of making and using thereof
US20080139649A1 (en) * 2005-01-27 2008-06-12 Barrow Colin J Fatty Acid-Benzenediol Derivatives and Methods of Making and Using Thereof
US20080206316A1 (en) * 2005-01-27 2008-08-28 Colin Barrow Chromium-Fatty Acid Compounds and Methods of Making and Using Thereof
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
US9968120B2 (en) * 2006-05-17 2018-05-15 Dsm Nutritional Products Ag Homogenized formulations containing microcapsules and methods of making and using thereof
US20070082063A1 (en) * 2005-10-11 2007-04-12 Douglas Bibus Risk assessment and correction of membrane damage of the upper GI tract
WO2007064871A2 (en) * 2005-12-02 2007-06-07 Howard Murad Diagnostic and treatment regimen for achieving body water homeostasis
CA2632949C (en) * 2005-12-21 2012-05-22 Brudy Technology, S.L. Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
WO2007089685A2 (en) * 2006-01-30 2007-08-09 University Of Georgia Research Foundation Compositions and methods for inducing adipose tissue cell death
NZ572529A (en) * 2006-04-07 2010-11-26 Ocean Nutrition Canada Ltd Emulsions and microcapsules with substances having low interfacial tension, methods of making and using thereof
US9056058B2 (en) * 2006-06-05 2015-06-16 Dsm Nutritional Products Microcapsules with improved shells
CN101641087B (zh) 2007-01-10 2013-08-21 加拿大海洋营养食品有限公司 素食的微胶囊
DE102007038849A1 (de) 2007-08-16 2009-02-19 Adscil Gmbh Verwendung von R(+)-alpha-Liponsäure zur Behandlung der kryptogenen Neuropathie
AU2008313248B2 (en) 2007-10-16 2012-04-26 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US9119826B2 (en) * 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
JPWO2012153832A1 (ja) 2011-05-12 2014-07-31 日本水産株式会社 炎症性疾患用皮膚外用組成物
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
WO2014151128A1 (en) * 2013-03-15 2014-09-25 Andrade Agustin Composition and method for treating neuropathy
US9226914B2 (en) * 2013-07-16 2016-01-05 Mead Johnson Nutrition Company Methods for promoting neuronal development and/or health
US9241923B2 (en) 2013-07-16 2016-01-26 Mead Johnson Nutrition Company Methods for promoting neuronal development and/or health
CN109232278A (zh) 2013-11-15 2019-01-18 Ds生物制药有限公司 多不饱和羟基脂肪酸的药学上可接受的盐
SG11201604500YA (en) 2013-12-04 2016-07-28 Nippon Suisan Kaisha Ltd Microbial oil, method for manufacturing microbial oil, concentrated microbial oil, and method for manufacturing concentrated microbial oil
EP3151825B1 (en) * 2014-06-04 2020-03-25 DS Biopharma Limited Pharmaceutical compositions comprising dgla and use of same
WO2016044167A1 (en) * 2014-09-15 2016-03-24 Abbott Laboratories Methods for increasing muscle strength and mobility in subjects experiencing significant physical inactivity using gamma linolenic acid
WO2016181221A1 (en) 2015-05-13 2016-11-17 Dignity Sciences Limited Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same
WO2017013492A1 (en) 2015-07-21 2017-01-26 Dignity Sciences Limited Compositions comprising 15-hepe for use in treating or preventing cancer and neurologic disease
AU2016370626B2 (en) 2015-12-18 2020-08-20 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US20240180891A1 (en) * 2020-12-22 2024-06-06 Buck Institute For Research On Aging Synergistic modulators of alpha-dicarbonyl detoxification and their use for inducing weight loss and the treatment of diabetic pathologies
CN114533715A (zh) * 2022-01-28 2022-05-27 上海市肺科医院 一种针对sting靶点的小分子抑制剂及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1176916B (it) * 1984-10-10 1987-08-18 Elvira Pistolesi Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
LU86220A1 (de) * 1985-12-19 1987-07-24 Chimicasa Gmbh Verfahren zur herstellung eines den cholesterin-und triglyceridgehalt senkenden pharmazeutischen praeparates
DE3615710A1 (de) * 1986-05-09 1987-11-26 Hoechst Ag Zubereitungen fuer die synthese von prostaglandinen und hydroxyfettsaeuren in biologischen systemen
US4937265A (en) * 1987-05-28 1990-06-26 Teijin Limited Antidiabetic method comprising 7-thiaprostaglandin E1 or its derivatives
EP0382066A3 (de) 1989-02-09 1992-01-08 ASTA Medica Aktiengesellschaft Verwendung von Dihydroliponsäure als Analgetikum, Antiphlogistikum und/oder Zytoprotektivum
RU2093154C1 (ru) * 1990-08-20 1997-10-20 Оленшлегер Герхард Фармкомпозиция для профилактики и лечения заболеваний, связанных с нарушением обмена веществ
US5602183A (en) 1991-03-01 1997-02-11 Warner-Lambert Company Dermatological wound healing compositions and methods for preparing and using same
US5569670A (en) * 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
DE4229914A1 (de) 1992-09-08 1994-03-10 Basf Ag Verbessertes Verfahren zur Herstellung von R/S-Ï-Liponsäure oder R/S-â-Liponsäure
DK0661051T3 (da) * 1993-10-11 2006-05-22 Viatris Gmbh Medikament til behandling af hypertension
US5472698A (en) * 1994-12-20 1995-12-05 Elizabeth Arden Co., Division Of Conopco, Inc. Composition for enhancing lipid production in skin
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
EP1021177A4 (en) * 1997-02-04 2002-05-15 John V Kosbab COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF VASCULAR DEGENERATIVE DISEASES
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment

Also Published As

Publication number Publication date
GB9816020D0 (en) 1998-09-23
DE69822832T2 (de) 2004-08-12
ZA986480B (en) 1999-01-22
KR100545630B1 (ko) 2006-01-24
EP1419769A1 (en) 2004-05-19
CA2297082C (en) 2008-04-22
CN1198608C (zh) 2005-04-27
NO20000303D0 (no) 2000-01-21
CA2297082A1 (en) 1999-02-04
TW565444B (en) 2003-12-11
PL338219A1 (en) 2000-10-09
HK1029281A1 (en) 2001-03-30
EP0994705A1 (en) 2000-04-26
NO20000303L (no) 2000-03-16
AU739876B2 (en) 2001-10-25
KR20010022148A (ko) 2001-03-15
DK0994705T3 (da) 2004-08-02
BG64349B1 (bg) 2004-11-30
BR9812102A (pt) 2000-07-18
NZ502278A (en) 2002-02-01
IL134090A0 (en) 2001-04-30
MY127930A (en) 2006-12-29
CN1265032A (zh) 2000-08-30
BG104141A (bg) 2000-10-31
JP4476479B2 (ja) 2010-06-09
IL134090A (en) 2006-08-20
CZ2000229A3 (en) 2001-05-16
HUP0002701A3 (en) 2001-03-28
EP0994705B1 (en) 2004-03-31
RU2205004C2 (ru) 2003-05-27
UA66363C2 (uk) 2004-05-17
GB2327347A (en) 1999-01-27
DE69822832D1 (de) 2004-05-06
GB2327347B (en) 2000-10-04
CN1679532A (zh) 2005-10-12
RO121318B1 (ro) 2007-03-30
NO327173B1 (no) 2009-05-04
WO1999004782A1 (en) 1999-02-04
JP2001510799A (ja) 2001-08-07
PL194059B1 (pl) 2007-04-30
HU226673B1 (en) 2009-06-29
ATE262900T1 (de) 2004-04-15
US6630157B1 (en) 2003-10-07
ES2214717T3 (es) 2004-09-16
CZ298527B6 (cs) 2007-10-24
TR200000178T2 (tr) 2000-08-21
GB9715444D0 (en) 1997-09-24
SK285836B6 (sk) 2007-09-06
SK842000A3 (en) 2001-02-12
AU8451998A (en) 1999-02-16
PT994705E (pt) 2004-08-31

Similar Documents

Publication Publication Date Title
HUP0002701A1 (hu) Esszenciális zsírsavakat és bioaktív diszulfidokat tartalmazó gyógyhatású és dietikus készítmények
IT1176916B (it) Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
HU9501206D0 (en) Pharmaceutical composition containing azithromycin
IL137848A0 (en) Indole-3-propionic acids, salts and esters thereof used as medicaments
DE68923819D1 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
DE69620291D1 (de) Nahrungszusammensetzungen in verschiedenen Formen
IL84032A (en) Totally or partially cross- linked esters of hyaluronic acid, salts of partially cross-linked esters, their preparation, pharmaceutical and cosmetic compositions containing them and sanitary, medical and surgical articles prepared therefrom
DK0725648T3 (da) Leverspecifikke farmaceutiske aktivstoffer
JPH0716076A (ja) 喫煙者のための調製物
UA29505C2 (uk) Фармацевтична композиція для лікування і/або профілактики розрідження кістки і спосіб лікування і/або профілактики розрідження кістки у ссавців
DE60000133D1 (de) Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
NO912943L (no) Anvendelse av nervonsyre og langkjedete fettsyrer for behandling av demyelineringsforstyrrelser.
DE69935995D1 (de) Polyungesättigen fettsäuren nährungsergänzung
ZA899176B (en) Use of acetyl d-carnitine in the therapeutic treatment of glaucoma and pharmaceutical compositions useful in such treatment
ITMI951359A0 (it) Formulazioni farmaceutiche e dietetiche per la profilassi e la cura di affezioni gastrointestinali
NO970317L (no) Anvendelse av DHA i en farmasöytisk blanding
NO990934D0 (no) Anvendelse av arakidonsyre og/eller dokosaheksansyre for fremstilling av et medikament for behandling av dyspraksi
AU1300001A (en) Gastroresistant tablets for alimentary, dietetic and therapeutic use
BG102556A (en) Orally applied pharmaceutical composition with modified release containing 5-asa, and a method for the treatment of intestinal diseases
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
ATE100095T1 (de) 2,2-dimethylchromenderivate, verfahren zur herstellung und diese enthaltende pharmazeutische zusammenstellungen.
ATE56148T1 (de) Orales dextran enthaltende zusammensetzungen.
KR940003552A (ko) 지방산을 이용한 석회화 예방 및 치료방법
KR930021178A (ko) 뼈 형성을 자극하는 약제
FI891210A7 (fi) Tiosulfiinihappojohdannaiset, niiden käyttö tulehdussairauksien käsitt elyyn sekä näitä aineita sisältävät lääkeaineet

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: MEDA PHARMA GMBH & CO. KG, DE

Free format text: FORMER OWNER(S): ASTA MEDICA A.G., DE; ASTA MEDICA HEALTH PRODUCTS GMBH & CO. KG, DE; VIATRIS GMBH & CO. KG, DE; VIATRIS GMBH & CO. KG, DE

MM4A Lapse of definitive patent protection due to non-payment of fees